Sapu003 Trial Delivers New Hope for Breast Cancer Patients
Sapu Nano received Human Research Ethics Committee approval in Australia to initiate a Phase 1 study of Sapu003, an...
Promising New Partnership Targets Triple-Negative Breast Cancer
Cellectar Biosciences plans to initiate a Phase 1b study of CLR 125 in triple-negative breast cancer in the fourth...
Japan Approves Burning Rock Test for Breast Cancer Drug
Japan’s Ministry of Health, Labour and Welfare has granted Manufacturing and Marketing Approval to the OncoGuide OncoScreen Plus CDx...
Breakthrough: Synendos Phase 1 Results Boost Mental Health
In a completed Phase 1 program, SYT-510 was administered to 60 healthy volunteers across single- and multiple-ascending dose cohorts...
Trethera Awarded $1.8M Grant for Crohn’s Drug Development
Trethera secured a $1.8 million NIH award to advance preclinical studies of TRE-515 in Crohn’s disease, following a prior...
IO Biotech’s Melanoma Data Selected for ESMO Presentation
IO Biotech will present primary Phase 3 results for its IDO/PD-L1-targeted cancer vaccine Cylembio (IO102-IO103) in combination with pembrolizumab...
Successful Dosing of Adults in XLRS LIGHTHOUSE Trial
Preliminary adult data from Atsena’s LIGHTHOUSE trial continue to show structural and functional improvement signals in X‑linked retinoschisis alongside...
Seres Therapeutics Implements Cost Cuts After FDA Feedback
Seres’ SER-155 previously showed a 77% relative reduction in bloodstream infections versus placebo in a Phase 1b allo-HSCT study,...
BPL-003 Trial Shows Victory for Treatment-Resistant Depression
In an open-label Phase 2a study of 13 patients with treatment-resistant depression, intranasal mebufotenin benzoate (BPL-003) delivered a mean...
Actuate Gives FDA Updated Clinical Data for EMA Interactions
Actuate’s randomized Phase 2 (n=286) in first-line metastatic pancreatic adenocarcinoma reported a statistically significant improvement in median overall survival...